Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug combo aims to tame rare kidney diseases

NCT ID NCT07522099

Disease control Sponsor: ADARx Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 04, 2026 · Updated 4 times

Summary

This Phase 2 study tests a new drug called ADX-038, alone or with another drug (telitacicept), in 30 Chinese adults with kidney diseases caused by an overactive complement system (IgA nephropathy, C3G, or IC-MPGN). The goal is to see if the treatment is safe and can help control the disease. Participants must have active kidney disease and meet other health criteria.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ADX-038 (siRNA drug) and telitacicept (fusion protein)
What this could lead to
If successful, this could point toward a new treatment option for certain complement-mediated kidney diseases, potentially slowing disease progression.
What could go wrong
This is an early Phase 2 trial with only 30 participants, so results may not apply to everyone. The combination therapy also adds complexity and potential side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2026

Expected to finish

Jan 2029

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Mean eGFR greater than or equal to 30 mL/min/1.73m2 * Clinical evidence of active kidney disease * Treated with supportive care including an ACE inhibitor or ARB if applicable * Willing to receive required vaccinations * Primary diagnosis of IgAN, C3G or IC-MPGN confirmed by a kidney biopsy Exclusion Criteria: * Previous kidney transplant or major solid organ transplant * Required renal replacement therapy for more than 72 hours * Rapidly progressive glomerular nephritis or acute kidney injury * History of recurrent invasive infection * Current or previous use of C5 or CFB inhibitors (such as eculizumab, ravulizumab or iptacopan) * Active TB, HIV or other systemic infection * Abnormal liver function

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Complement 3 glomerulopathy (C3G) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

complement 3 glomerulopathy IgA glomerulonephritis immunoglobulin-mediated membranoproliferative glomerulonephritis membranoproliferative glomerulonephritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Complement 3 glomerulopathy (C3G) Ic-MPGN Immunoglobulin A nephropathy (IGAN)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    9 sites. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • ADARx Clinical Site

    RECRUITING

    Shenzhen, Guangdong, 518100, China

  • ADARx Clinical Site

    RECRUITING

    Guiyang, Guizhou, China

  • ADARx Clinical Site

    RECRUITING

    Zhengzhou, Henan, China

  • ADARx Clinical Site

    RECRUITING

    Baotou, Inner Mongolia, 014000, China

  • ADARx Clinical Site

    RECRUITING

    Wuxi, Jiangsu, 214000, China

  • ADARx Clinical Site

    RECRUITING

    Yantai, Shandong, 264008, China

  • ADARx Clinical Site

    RECRUITING

    Beijing, 100034, China

  • ADARx Clinical Site

    RECRUITING

    Shandong, China

  • ADARx Clinical Site

    RECRUITING

    Shanghai, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.